HRP20030974A2 - Composition and method for increasing cell density in cell cultures infected with lentivirus - Google Patents
Composition and method for increasing cell density in cell cultures infected with lentivirus Download PDFInfo
- Publication number
- HRP20030974A2 HRP20030974A2 HR20030974A HRP20030974A HRP20030974A2 HR P20030974 A2 HRP20030974 A2 HR P20030974A2 HR 20030974 A HR20030974 A HR 20030974A HR P20030974 A HRP20030974 A HR P20030974A HR P20030974 A2 HRP20030974 A2 HR P20030974A2
- Authority
- HR
- Croatia
- Prior art keywords
- cell culture
- neomycin
- cell
- virus
- amount
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 241000713666 Lentivirus Species 0.000 title claims description 23
- 230000003115 biocidal effect Effects 0.000 claims abstract description 13
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 61
- 229930193140 Neomycin Natural products 0.000 claims description 45
- 229960004927 neomycin Drugs 0.000 claims description 45
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 24
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 17
- 230000012010 growth Effects 0.000 claims description 14
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 108010093965 Polymyxin B Proteins 0.000 claims description 9
- 229920000024 polymyxin B Polymers 0.000 claims description 9
- 229960005266 polymyxin b Drugs 0.000 claims description 9
- 239000012592 cell culture supplement Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 208000010094 Visna Diseases 0.000 claims description 5
- 239000012888 bovine serum Substances 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 238000010899 nucleation Methods 0.000 claims 1
- 230000010261 cell growth Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282324 Felis Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000009724 equine infectious anemia Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000713747 Ovine lentivirus Species 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29009601P | 2001-05-10 | 2001-05-10 | |
| PCT/US2002/014271 WO2002091994A2 (en) | 2001-05-10 | 2002-05-03 | Composition and method for increasing cell density in cell cultures infected with lentivirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030974A2 true HRP20030974A2 (en) | 2004-02-29 |
Family
ID=23114512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030974A HRP20030974A2 (en) | 2001-05-10 | 2003-11-24 | Composition and method for increasing cell density in cell cultures infected with lentivirus |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7160721B2 (zh) |
| EP (2) | EP2298343A1 (zh) |
| JP (1) | JP4283544B2 (zh) |
| KR (1) | KR20040029981A (zh) |
| CN (1) | CN1326992C (zh) |
| AT (1) | ATE521364T1 (zh) |
| AU (1) | AU2002342568B2 (zh) |
| BG (1) | BG108315A (zh) |
| BR (1) | BR0209482A (zh) |
| CA (1) | CA2446131C (zh) |
| CY (1) | CY1112123T1 (zh) |
| CZ (1) | CZ20033046A3 (zh) |
| DK (1) | DK1385540T3 (zh) |
| ES (1) | ES2369846T3 (zh) |
| HR (1) | HRP20030974A2 (zh) |
| HU (1) | HUP0400283A2 (zh) |
| MX (1) | MXPA03010208A (zh) |
| NO (1) | NO20034961L (zh) |
| NZ (1) | NZ529326A (zh) |
| PL (1) | PL373847A1 (zh) |
| PT (1) | PT1385540E (zh) |
| SI (1) | SI1385540T1 (zh) |
| WO (1) | WO2002091994A2 (zh) |
| YU (1) | YU88703A (zh) |
| ZA (1) | ZA200309556B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215107A (en) * | 1978-12-29 | 1980-07-29 | Merck & Co., Inc. | Parainfluenza virus vaccine and its preparation |
| JPS57194787A (en) * | 1981-05-28 | 1982-11-30 | Ajinomoto Co Inc | Culture medium for animal cell |
| US6107077A (en) | 1987-08-26 | 2000-08-22 | Yamamoto; Janet K. | Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines |
| JPH05509306A (ja) * | 1990-07-30 | 1993-12-22 | ジ・アップジョン・カンパニー | ヒト・レトロウイルスの抑制およびエイズの治療のためのヘキサ―Ｎ―（ｏ―ヒドロキシベンジル）ネオマイシンＢ |
| US5534408A (en) * | 1993-09-24 | 1996-07-09 | University Of Massachusetts Medical Center | 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding |
| CA2147605A1 (en) * | 1992-10-23 | 1994-05-11 | Michael R. Green | Small molecule inhibition of rna/ligand binding |
| PT1820512E (pt) | 1994-05-10 | 2013-10-09 | Boehringer Ingelheim Vetmed | Vacina viva modificada melhorada contra brsv |
| DE69636440D1 (de) | 1995-08-25 | 2006-09-21 | Univ Florida | IL-2 unabhängige T-Zellen der Katze |
-
2002
- 2002-05-03 PT PT02769679T patent/PT1385540E/pt unknown
- 2002-05-03 BR BRPI0209482-7A patent/BR0209482A/pt not_active IP Right Cessation
- 2002-05-03 CN CNB028096002A patent/CN1326992C/zh not_active Expired - Lifetime
- 2002-05-03 HU HU0400283A patent/HUP0400283A2/hu unknown
- 2002-05-03 AT AT02769679T patent/ATE521364T1/de active
- 2002-05-03 KR KR10-2003-7014613A patent/KR20040029981A/ko not_active Application Discontinuation
- 2002-05-03 CA CA2446131A patent/CA2446131C/en not_active Expired - Lifetime
- 2002-05-03 EP EP10183838A patent/EP2298343A1/en not_active Withdrawn
- 2002-05-03 SI SI200230960T patent/SI1385540T1/sl unknown
- 2002-05-03 ES ES02769679T patent/ES2369846T3/es not_active Expired - Lifetime
- 2002-05-03 EP EP02769679A patent/EP1385540B1/en not_active Expired - Lifetime
- 2002-05-03 PL PL02373847A patent/PL373847A1/xx not_active Application Discontinuation
- 2002-05-03 NZ NZ529326A patent/NZ529326A/en not_active IP Right Cessation
- 2002-05-03 DK DK02769679.8T patent/DK1385540T3/da active
- 2002-05-03 AU AU2002342568A patent/AU2002342568B2/en not_active Expired
- 2002-05-03 CZ CZ20033046A patent/CZ20033046A3/cs unknown
- 2002-05-03 JP JP2002588913A patent/JP4283544B2/ja not_active Expired - Lifetime
- 2002-05-03 YU YU88703A patent/YU88703A/sh unknown
- 2002-05-03 MX MXPA03010208A patent/MXPA03010208A/es active IP Right Grant
- 2002-05-03 WO PCT/US2002/014271 patent/WO2002091994A2/en active Search and Examination
- 2002-05-07 US US10/140,172 patent/US7160721B2/en not_active Expired - Lifetime
-
2003
- 2003-11-05 BG BG108315A patent/BG108315A/bg unknown
- 2003-11-07 NO NO20034961A patent/NO20034961L/no not_active Application Discontinuation
- 2003-11-24 HR HR20030974A patent/HRP20030974A2/hr not_active Application Discontinuation
- 2003-12-09 ZA ZA200309556A patent/ZA200309556B/xx unknown
-
2011
- 2011-09-23 CY CY20111100925T patent/CY1112123T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002091994A3 (en) | 2003-05-08 |
| CZ20033046A3 (en) | 2004-03-17 |
| NO20034961L (no) | 2003-12-01 |
| CY1112123T1 (el) | 2015-11-04 |
| WO2002091994A2 (en) | 2002-11-21 |
| HUP0400283A2 (en) | 2007-08-28 |
| BG108315A (bg) | 2005-03-31 |
| EP1385540A2 (en) | 2004-02-04 |
| SI1385540T1 (sl) | 2011-10-28 |
| US7160721B2 (en) | 2007-01-09 |
| EP2298343A1 (en) | 2011-03-23 |
| CN1514734A (zh) | 2004-07-21 |
| KR20040029981A (ko) | 2004-04-08 |
| ES2369846T3 (es) | 2011-12-07 |
| YU88703A (sh) | 2006-05-25 |
| DK1385540T3 (da) | 2011-10-24 |
| JP2005508139A (ja) | 2005-03-31 |
| ATE521364T1 (de) | 2011-09-15 |
| CA2446131C (en) | 2013-07-02 |
| JP4283544B2 (ja) | 2009-06-24 |
| NZ529326A (en) | 2006-09-29 |
| BR0209482A (pt) | 2007-01-02 |
| PT1385540E (pt) | 2011-10-21 |
| ZA200309556B (en) | 2005-02-23 |
| AU2002342568B2 (en) | 2007-11-01 |
| MXPA03010208A (es) | 2004-03-10 |
| EP1385540B1 (en) | 2011-08-24 |
| CN1326992C (zh) | 2007-07-18 |
| EP1385540A4 (en) | 2004-12-01 |
| NO20034961D0 (no) | 2003-11-07 |
| PL373847A1 (en) | 2005-09-19 |
| CA2446131A1 (en) | 2002-11-21 |
| US20020197714A1 (en) | 2002-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schuetze et al. | The Ets-related transcription factor PU. 1 immortalizes erythroblasts | |
| Nadala et al. | Primary culture of lymphoid, nerve, and ovary cells from Penaeus stylirostris and Penaeus vannamei | |
| Wilson et al. | Viral and cellular factors governing hamster cell infection by murine and gibbon ape leukemia viruses | |
| DE50214630D1 (de) | Verfahren zur grosstechnischen herstellung von impfstoffen | |
| Ilyinskii et al. | The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys | |
| HRP20030974A2 (en) | Composition and method for increasing cell density in cell cultures infected with lentivirus | |
| Narayan et al. | Role of macrophages in lentivirus infections | |
| DE60313743T2 (de) | Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen | |
| WO2006056853A1 (en) | Methods for cultivating lawsonia intracellularis | |
| AU2002342568A1 (en) | Composition and method for increasing cell density in cell cultures infected with lentivirus | |
| CN1700929A (zh) | 含有禽吸收障碍综合征相关病毒的疫苗及其给药方法 | |
| Bouillant et al. | The persistent infection of a canine thymus cell line by equine infectious anaemia virus and preliminary data on the production of viral antigens | |
| US11344523B2 (en) | Composition for use in treating rotavirus infection | |
| Valtink et al. | Pseudotyping and culture conditions affect efficiency and cytotoxicity of retroviral gene transfer to human corneal endothelial cells | |
| CN114891718B (zh) | 用于悬浮培养骨髓细胞的培养基、制备方法、应用和诱导骨髓源细胞分化为巨噬细胞的方法 | |
| US5112756A (en) | Continuous production of bovine Maedi-Visna-like viral antigens in Cf2Th cells | |
| WO2024101249A1 (ja) | ウイルス感染抑制剤 | |
| Hayes et al. | Pathogenicity of Mycoplasma fermentans and Mycoplasma penetrans in experimentally infected chicken embryos | |
| RU2819260C2 (ru) | Бессывороточная среда для производства птичьей вакцины и ее использование | |
| Simeonov et al. | Effects of chicken anaemia virus on experimental leukosis, induced by avian myelocytomatosis virus MC29. | |
| TW202434267A (zh) | 病毒感染抑制劑 | |
| KR20240059823A (ko) | 국내 발생된 돼지 델타코로나바이러스의 분리 배양 방법 | |
| CN115747138A (zh) | 一种hek 293细胞培养基及其应用 | |
| Therrien | The effects of polybrene and puromycin on viral production and replication | |
| JPH06113834A (ja) | フグの口白症の予防ワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20070426 Year of fee payment: 6 |
|
| ODBI | Application refused |